“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET)

Cancer Treatment Reviews (1996) 22, 425-436 Joan Maurel*, Rafael Rosell*$ Juan Carlos Lorenzot Departments of *Medical Oncology t Pathology, University Hospital Germans Trias i Pujol, Box 72, 08916 Badalo, Barcelo, Spain Introduction Despite a marked decline in mortality of Ewing’s peripheral primitive neuroectodermal tumours () patients in the last two decades with the advent of chemotherapy regimens better surgical radiation procedures, a subset of patients with poor prognostic features still does not respond favourably with stard treatments. Few specific prospective studies have been addressed to this patient population, available data of more intensive schedules are clearly insufficient. The purpose of this review is to provide oncologists with details of biological features, the tural history, stard new approaches to the treatment of Ewing’s . Epidemiology biology Ewing’s (ES) is a highly malignt tumour of bone soft tissue composed of small, round, blue cells. With recent advances in immunohistology, closely related entities referred to as malignt primitive neuroectodermal tumours () warrant being considered as a single entity, Ewing’s tumours (ESTs). The histopathogenesis is still being debated but a probable neural origin (I, 2) has been suggested. lmmunohistochemical electron microscopy features help to differentiate ES from . Contradictory reports on the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Treatment Reviews Elsevier
Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.